Cipla gets approval to import Moderna's COVID-19 vaccine in India

29 Jun 2021 Evaluate

Cipla has received approval from India's drug regulator Drugs Controller General of India (DCGI) to import Moderna's COVID-19 vaccine for restricted emergency use in the country. Moderna's vaccine will be the fourth COVID-19 jab to be available in India after Covishield, Covaxin and Sputnik.

This permission is for restricted use in emergency situations in public interest. The firm has to submit 7 days safety assessment of the vaccine in first 100 beneficiaries before rolling out of vaccine for further immunisation programme, according to the approval order.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1499.20 7.80 (0.52%)
31-Dec-2025 11:34 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.20
Dr. Reddys Lab 1266.15
Cipla 1499.20
Zydus Lifesciences 912.10
Lupin 2093.90
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×